Core Viewpoint - Enwei Pharmaceutical has completed its 2024 annual equity distribution, announcing a cash dividend of 1.8 yuan per 10 shares (tax included), marking a continuous decline in per-share dividends since its listing [1][2]. Dividend Distribution - The 2024 equity distribution plan is based on a total share capital of 102,891,887 shares, excluding 1,815,526 repurchased shares, resulting in a base of 101,076,361 shares for the cash dividend distribution [1]. - The total cash dividend amount for 2024 is 18,193,744.98 yuan, which represents 48.65% of the annual net profit attributable to shareholders [1][3]. - Historical cash dividends per 10 shares for 2022, 2023, and 2024 are 16 yuan, 8 yuan (with a stock increase of 4.8 shares), and 1.8 yuan respectively, indicating a significant reduction over the years [1][2]. Profitability Trends - Enwei Pharmaceutical's net profit has shown a notable decline over the past three years, with figures of 0.99 billion yuan, 1.02 billion yuan, 0.68 billion yuan, 0.86 billion yuan, and 0.37 billion yuan from 2020 to 2024, respectively [3]. - The net profit for 2024 has decreased by 56.56% compared to the previous year [3]. Business Focus - Enwei Pharmaceutical specializes in the research, production, and sales of traditional Chinese medicine, chemical drugs, and health care products, focusing on gynecological products, pediatric medications, respiratory system drugs, and health care items [5]. - The core product of the company is the gynecological external wash "Jier Yin Wash," with gynecological product revenue for 2024 amounting to approximately 4.19 billion yuan, accounting for 51.55% of total revenue and a gross margin of 59.17% [5].
上市近三年,恩威医药现金分红“打折”:从每股1.6元下滑至每股0.18元